Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has received approval from the National Medical Products Administration (NMPA) to conduct an open-label, multi-center Phase Ib/II clinical study. The study will assess the efficacy of three of the company’s novel pipeline candidates in combination regimens against general solid tumors. The drugs in focus are SHR-8068, adebrelimab (SHR-1316), and SHR-2002, with bevacizumab (Avastin) also included in the study.
Adebrelimab, a programmed death-ligand 1 (PD-L1) monoclonal antibody (mAb) developed by Hengrui, was approved in China for the first-line treatment of extensive stage small-cell lung cancer (ES-SCLC) in combination with chemotherapy in March of the previous year.
SHR-2002 is noted as a PVRIG/TIGIT bispecific antibody (BsAb), marking it as the first of its kind to reach the clinical stages globally.
SHR-8068 is an in-licensed monoclonal antibody targeting CTLA-4. Currently, only two similar products, ipilimumab and tremelimumab, are commercially available worldwide.- Flcube.com
